Cocrystal Pharma Inc. (NASDAQ: COCP) stock gains by 17.44% in the current market trading session. Cocrystal Pharma, Inc. is a clinical-stage biotechnology firm focused on finding and creating new antiviral medicines that tackle coronaviruses (particularly SARS-CoV-2), influenza viruses, hepatitis C virus, and norovirus replication.
>> 7 Top Picks for the Post-Pandemic Economy <<
Significant Development in COCP stock
SARS-CoV-2 3CL protease leads CDI-45205 and various analogs demonstrated significant in vitro efficacy against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants, according to Cocrystal Pharma. CDI-45205 and analogs showed broad-spectrum efficacy against the SARS-CoV-2 Alpha and Beta variants, exceeding the activity shown with the Wuhan strain, according to Cocrystal.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
COCP’s unique drug discovery platform technology is still being used to create SARS-CoV-2 oral protease inhibitors and replication inhibitors. Cocrystal’s method to drug development offers a one-of-a-kind avenue to developing broad-spectrum coronavirus antivirals for SARS-CoV-2 and other emerging variants.
What is CDI-45205?
Cocrystal stated in December 2020 that it has chosen CDI-45205 as their main coronavirus research candidate from a pool of protease inhibitors received under the KSURF agreements. In intraperitoneal injection pharmacokinetic studies in mice and rats, CDI-45205 showed good bioavailability and no cytotoxicity against a range of human cell lines. In addition, CDI-45205 has a high synergistic impact with remdesivir. Furthermore, solid evidence animal research found that daily injections of CDI-45205 in MERS-CoV-infected mice had excellent in vivo effectiveness. Cocrystal is continuing to test CDI-45205 after receiving good preliminary pharmacokinetic data.
>> 7 Top Picks for the Post-Pandemic Economy <<
Sam Lee, Cocrystal’s President, and interim co-CEO stated,
These SARS-CoV-2 in vitro data also suggest that Cocrystal’s SARS-CoV-2 3CL protease inhibitor CDI-45205 might be a viable therapy for COVID-19 induced by SARS-CoV-2. It’s developing variants, such as the fast-spreading Delta version, which is quickly becoming the most common COVID-19 variant worldwide. CDI-45205 previously shown good in vivo effectiveness in a MERS-CoV-2 infected animal model, thus broad-spectrum action against these SARS-CoV-2 variants is quite promising.
